Skip to main content
. 2022 Jun 6;40(34):3952–3964. doi: 10.1200/JCO.22.01003

FIG A1.

FIG A1.

Plots of the log of the cumulative hazard for PFS by investigator in (A) the homologous recombination-deficiency population and (B) the intent-to-treat population and PFS by blinded independent central review for the same populations (C and D, respectively). PFS, progression-free survival.